Tag: Developers Code

Continuous Delivery

Mitsubishi Tanabe Pharma Shares Phase 2 Results for ND0612 Subcutaneous Levodopa Therapy in Advanced Parkinson’s Disease

Phase 2 trial data show that continuous subcutaneous delivery of carbidopa/levodopa via ND0612 improved motor function and quality of life in advanced Parkinson’s patients within days. A global Phase 3 study is now underway.